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Abstract
Background: To estimate, from the perspective of the Chinese healthcare system, the economic outcomes of five different
first-line strategies among patients with metastatic renal cell carcinoma (mRCC).
Methods and Findings: A decision-analytic model was developed to simulate the lifetime disease course associated with
renal cell carcinoma. The health and economic outcomes of five first-line strategies (interferon-alfa, interleukin-2,
interleukin-2 plus interferon-alfa, sunitinib and bevacizumab plus interferon-alfa) were estimated and assessed by indirect
comparison. The clinical and utility data were taken from published studies. The cost data were estimated from local charge
data and current Chinese practices. Sensitivity analyses were used to explore the impact of uncertainty regarding the
results. The impact of the sunitinib patient assistant program (SPAP) was evaluated via scenario analysis. The base-case
analysis showed that the sunitinib strategy yielded the maximum health benefits: 2.71 life years and 1.40 quality-adjusted
life-years (QALY). The marginal cost-effectiveness (cost per additional QALY) gained via the sunitinib strategy compared with
the conventional strategy was $220,384 (without SPAP, interleukin-2 plus interferon-alfa and bevacizumab plus interferon-
alfa were dominated) and $16,993 (with SPAP, interferon-alfa, interleukin-2 plus interferon-alfa and bevacizumab plus
interferon-alfa were dominated). In general, the results were sensitive to the hazard ratio of progression-free survival. The
probabilistic sensitivity analysis demonstrated that the sunitinib strategy with SPAP was the most cost-effective approach
when the willingness-to-pay threshold was over $16,000.
Conclusions: Our analysis suggests that traditional cytokine therapy is the cost-effective option in the Chinese healthcare
setting. In some relatively developed regions, sunitinib with SPAP may be a favorable cost-effective alternative for mRCC.
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Introduction
Renal cell carcinoma (RCC), the most common type of kidney
cancer, accounts for about 3% of all human malignancies. It is
estimated that nearly 30% of the patients with RCC have distant
metastatic disease at presentation and that half of those with
localised disease subsequently develop metastases during the
course of their disease [1,2]. The median overall survival for
metastatic RCC patients is 10 months, and the 5-year survival rate
is 5–15%, even when all visible disease is cleared by metasta-
sectomy and nephrectomy [3,4]. RCC is insensitive to traditional
cytotoxic agents and radiation therapies. At present, the most
widely used regimens for metastatic RCC (mRCC) are cytokine
therapies, including interferon-alfa and interleukin-2, which in
previous studies showed response rates of only 10–20% and
resulted in debilitating adverse effects [5,6,7]. Studies of cytokine
therapies with or without chemotherapy have shown short-term
partial response rates of up to 20–35% [8,9]. New treatments are
needed to develop strategies for controlling metastatic disease and
improving quality of life.
Recently, targeted pharmacological therapies (e.g., sunitinib,
sorafenib, bevacizumab, pazopanib, axitinib and temsirolimus)
have been developed for RCC treatment [10]. Among them,
sunitinib and bevacizumab (combined with interferon-alfa) have
been accepted as first-line therapy options for patients with
mRCC. Sunitinib is an orally administered multi-target inhibitor
of vascular endothelial growth factor (VEGF) and platelet-derived
growth factor (PDGF); bevacizumab is a humanised monoclonal
antibody that selectively inhibits VEGF-A, which is involved in
cancer angiogenesis. These targeted therapies can improve
progression-free survival (PFS) and overall survival (OS)
[11,12,13,14]. However, their substantial cost restricts their
widespread use, especially in health resource–limited regions. An
evaluation of the cost-effectiveness of these new therapies is
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32530important for improving resource allocation efficiency. A few
economic studies of these new therapies have been reported
[15,16,17,18]. However, there have been few cost-effectiveness
analyses conducted in resource-limited settings, where the front-
line therapy for mRCC still involves traditional chemotherapy and
cytokine therapy.
In the current study, we evaluated the long-term economic
outcomes of five first-line mRCC regimens based on clinical practice
and recommendations: [19] sunitinib, bevacizumab plus interferon-
alfa, interferon-alfa, interleukin-2, and interleukin-2 plus interferon-
alfa.Becausethefollow-up timesofmostclinicaltrialsdo not focuson
the lifetime course of the disease, head-to-head comparisons among
several different therapies are rarely reported. Thus, mathematical
modelling techniques must be used to supply decision making
information. A perspective of Chinese healthcare system was adopted
to assist in determining the direct economic value of the five different
first-line therapies, given the willingness-to-pay threshold of Chinese
and Shanghai residents that is associated with the per capita GDP per
quality-adjusted life-year (QALY) gained. The analysis excluded
indirect societal costs (i.e., productivity or caregiver costs).
Methods
Analytical overview
With the R software package (version 2.13.0; R Development
Core Team, Vienna, Austria), we used a previously developed
Markov model to simulate the transition of a cohort of individuals
with mRCC based on the clinical course [20]. We used this model
to estimate and compare the lifetime direct medical costs and health
outcomes associated with different first-line strategies for mRCC
from the perspective of the Chinese healthcare system. The future
costs and benefits were discounted using a 3% annual discount rate.
Although multiple agents for mRCC have been evaluated in
clinical trials, the most commonly used first-line strategies are
interferon-alfa, interleukin-2, sunitinib and bevacizumab [19].
Therefore, the cost and effectiveness of the five first-line strategies
(sunitinib, bevacizumab plus interferon-alfa, interferon-alfa, inter-
leukin-2 and interleukin-2 plus interferon-alfa) were evaluated and
compared. Because of the absence of head-to-head clinical trials
comparing these five first-line strategies, an indirect comparison
was performed following a well-established approach [15,17,21].
Because the affordability of sunitinib in China can be a challenge,
the Sunitinib Patient Assistance Program (SPAP) was introduced
to make sunitinib available to eligible patients. Currently, the
SPAP requires RCC patients to pay for three cycles of sunitinib,
after which they will receive donations of sunitinib until the end of
their treatment [22]. Therefore, the scenario analyses included the
importance of SPAP for sunitinib.
Four types of parameters were inputs for the model: transition
probabilities, which reflect the probabilities of moving between
health states at each cycle; event proportions, which govern the
ratios of events; direct medical costs, which were estimated based
on health resource consumption; and health state utilities, which
project the health-related quality of life for different health states.
These data were derived from the published literature or from
local health systems.
Cost-effectiveness ratios were calculated to evaluate the
outcomes of the different strategies. The main health outcomes
were presented by quality-adjusted life-year (QALY). The results
were presented as an incremental cost-effectiveness ratio (ICER).
Figure 1. The model structure illustrating the five first-line strategies for treating mRCC.
doi:10.1371/journal.pone.0032530.g001
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A decision-analytic Markov model was used to compare the
lifetime clinical progression, costs and utilities of treating mRCC
with sunitinib, bevacizumab plus interferon-alfa, interferon-alfa,
interleukin-2 and interleukin-2 plus interferon-alfa. Three discrete
health states reflecting different characteristics of the disease were
identified: progression-free survival (PFS), progressed survival (PS)
and death. The structure of the model is shown in Figure 1. To be
consistent with other economic evaluations in the literature, a 10-
year time horizon was used to determine the lifetime outcomes
[16,17]. In the Markov model, the cycle length was 6 weeks and
the entry state was progression-free survival. During each 6-week
cycle, the patients either remained in their assigned health state or
progressed to a new health state. The hypothetical patient
demographics, when entering the model, matched those of the
patients in the pivotal clinical trials: histologically proven renal cell
carcinoma, advanced metastatic disease, finding of at least one
measurable lesion, a World Health Organization (WHO) or
Eastern Cooperative Oncology Group (ECOG) performance
status (PS) of 0 or 1, and adequate organ function [5,11,12].
Clinical data and adjusted indirect comparison
We performed a literature search in the following electronic
databases for the pivotal clinical trials pertaining to mRCC
treatments: PubMed, EMBASE, CINAHL, AltHealthWatch, the
Cochrane Library, and the National Library of Science and
Technology. The search covered the periods from the databases
inceptions to the end of July 2011. However, no clinical trial
directly comparing these five strategies was identified. Therefore,
an indirect comparison of key clinical trials was performed.
Clinical effectiveness data, including HR (hazard ratio), were
separately extracted from the four multicenter, randomised-
controlled clinical trials that had interferon-alfa as a common
comparator; each of these trials constituted level 1 evidence [23].
The AVOREN Trial randomised 649 patients with mRCC to
receive interferon-alfa 2a and bevacizumab (n=327) or placebo
and interferon-alfa 2a (n=322). The median PFS was significantly
longer in the bevacizumab plus interferon-alfa group than in the
control group (10.2 vs. 5.4 months, HR 0.63, 95% CI 0.52–0.75,
p=0.0001). The median OS was also longer, although the
difference was not statistically significant (23.3 vs. 21.3 months,
HR 0.91, 95% CI 0.76–1.10, p=0.336) [11,14].
In the sunitinib trial, 750 mRCC patients were randomly
assigned to sunitinib or to interferon-alfa. The median PFS in the
sunitinib arm (11 months) was significantly longer than in the
interferon-alfa arm (5 months), corresponding to an HR of 0.42
(95% CI 0.32–0.54, P,0.001). The median OS was greater in the
sunitinib arm than in the interferon-alfa arm (26.4 vs. 21.8
months, HR 0.821, 95% CI 0.673–1.001, P =0.051) [12,13].
The MRC RE04/EORTC GU 30012 trial enrolled 1,006
advanced mRCC patients who were randomly allocated (1 to 1) by
minimisation to receive interferon-alfa alone or combination
therapy with interferon-alfa, interleukin-2, and fluorouracil. After
a median follow-up of nearly 37 months, the median OS was 18.8
months for the patients receiving interferon-alfa versus 18.6
months for those receiving the combination therapy (HR 1.05,
95% CI 0.90–1.21, p=0.55). There was no evidence that the
median PFS differed between the treatment groups (5.5 vs. 5.3
months, HR 1.02, 95% CI 0.89–1.16, p=0.81) [5].
The clinical trial reported by Groupe Francais d’Immunother-
apie enrolled 425 mRCC patients who were randomly assigned
to receive interleukin-2, interferon-alfa alone or both. There was
no significant difference in OS among the three groups.
However, the PFS in the combined cytokine treatment group
was significantly higher than in the other two groups (P=0.01)
[6]. The HR of the interleukin-2 group compared with the
interferon-alfa group was derived from a previous economic study
(HR of PFS 0.895 [95% CI 0.680–1.202], HR of OS 1.083 [95%
CI 0.718–1.394]) [17].
Indirect comparisons of the five strategies were conducted
using a hypothetical average interferon-alfa (reference) survival
rate. Weibull survival models were fitted to the Kaplan-Meier
PFS and OS data for interferon-alfa. The estimated Weibull
parameters, scale (l) and shape (c), and their SEs and correlation
coefficients are shown in Table 1. The variations in the
interferon-alfa survival rates may be attributable to variations in
baseline demographics or disease severities. Based on the Weibull
model, the PFS and OS rates for interferon-alfa in the four trials
were calculated at each cycle. The reference survival rates at each
cycle were calculated and weighted according to patient numbers
[21]. Once a survival rate was calculated, the survival rates for
the active strategies were adjusted by the following formula:
Sactive strategies=(S interferon-alfa(reference))
HR. All HR data is present-
ed in Table 2. We did not use the Weibull model to fit the
Table 1. The parameters of the Weibull curves fitted to the interferon-alfa Kaplan-Meier survival data from four pivotal clinical
trials.
Scale Shape
Trials Mean SE Mean SE Adjusted R
2 Correlation Coefficient Reference
Progression-free survival
Negrier, S. 1998 trial 0.360096 0.0149185 0.7626 0.0237 0.9216 20.99954 [6]
Escudier, B. 2007 trial 0.174161 0.004828 1.024 0.017 0.9862 20.99962 [11]
Motzer, R. J. 2007 trial 0.2447073 0.0078566 0.7914 0.0215 0.9565 20.99954 [12]
Gore, M. E. 2010 trial 0.2288074 0.0094682 0.8361 0.0215 0.9605 20.99962 [5]
Overall survival
Negrier, S. 1998 trial 0.064372 0.000922 0.9871 0.0066 0.9959 20.99973 [6]
Motzer, R. J. 2009 trial 0.0476218 0.0012449 0.9666 0.0118 0.9928 20.999673 [13]
Escudier, B. 2010 trial 0.043549 0.000682 1.015 0.007 0.9978 20.99911 [14]
Gore, M. E. 2010 trial 0.038574 0.000943 1.099 0.011 0.9861 20.99911 [5]
doi:10.1371/journal.pone.0032530.t001
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doi:10.1371/journal.pone.0032530.g002
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there are two important advantages to using the HRs to derive
the survival curves, as mentioned by Hoyle, M. et al [16]. First,
the method allows for the number of patients at risk on the
Kaplan-Meier curve. Second, it allows for the analysis of
uncertainty in clinical effectiveness by changing the HRs. The
PFS and OS HRs between the alternative strategies and
interferon-alfa were derived from the previously mentioned
Table 2. HR and probabilities of SAEs.
Treatmentstrategy
Parameters interferon-alfa
Bevacizumab
plus
interferon-alfa Sunitinib Interleukin-2
Interleukin-2 plus
interferon-alfa Source
HR
PFS(95% CI) - 0.63(0.52–0.75) 0.42(0.32–0.54) 0.895(0.68–1.202) 1.02(0.89–1.16) [5,6,11,12,17]
OS(95% CI) - 0.91(0.76–1.1) 0.821(0.673–1.001) 1.083(0.718–1.394) 1.05(0.9–1.21) [5,6,13,14,17]
Probability of SAEs
*
Neutropenia(range
#) 1(0.9–1.1) 4(3.6–4.4) 12(10.8–13.2) 5(4.5–5.5) 5(4.5–5.5) [5,6,11,12]
Anaemia(range
#) 3(2.7–3.3) 3(2.7–3.3) 4(3.6–4.4) 2(1.8–2.2) 2(1.8–2.2) [5,6,11,12]
Thrombocytopenia(range
#) 0.99(0.89–1.09) 2(1.8–2.2) 8(7.2–8.8) 0.99(0.89–1.09)
$ 0.99(0.89–1.09)
$ [5,6,11,12]
Nausea(range
#) 2(1.8–2.2) 3(2.7–3.3) 4(3.6–4.4) 5(4.5–5.5) 5(4.5–5.5) [5,6,11,12]
Fatigue/Asthenia(range
#) 18(16.2–19.8) 12(10.8–13.2) 7(6.3–7.7) 25(22.5–27.5)
& 25(22.5–27.5) [5,6,11,12]
Hypertension(range
#) 0.66(0.59–0.72) 3(2.7–3.3) 8(7.2–8.8) 4(3.6–4.4) 4(3.6–4.4) [5,6,11,12]
Proteinuria(range
#)0
1 7(6.3–7.7) 0
1 0
1 0
1 [5,6,11,12]
*Probabilities are presented as percentages.
#The range is from 90% to 110% of the mean.
$We assumed that the probabilities were similar to those in the AVOREN Trial.
&We assumed the that probabilities were similar to those in the Gore, M. E. 2010 trial.
1Rare data were reported; we assumed that the probability of proteinuria was zero.
doi:10.1371/journal.pone.0032530.t002
Table 3. Base-Case Cost Estimates ($, year 2011 values) and Utilities.
Parameter Median Cost (US $) Range
* (US$) Description and Reference
Cost
Sunitinib per 12.5 mg 71.5 fixed Local charge [24]
Bevacizumab per 100 mg 815.1 fixed Local charge [24]
Interferon-alfa per 300 MU 6.5 4.2–6.9 Local charge [24]
Interleukin-2 per 50 MU 13.4 12–13.8 Local charge [24]
Sorafenib per 400 mg 64.5 fixed Local charge [24]
Morphine sulphate per 300 mg 1.4 1.3–1.6 Local charge [24]
Drug administration 18.5 16.6–20.3 Local charge [24]
Routine follow-up of patients per unit 38.5 30.8–53.8 Local charge [24]
Expenditures of SAEs (per event)
Neutropenia 461.5 415.4–507.7 Calculation
Anaemia 531.7 478.5–584.9 Calculation
Thrombocytopenia 3551.7 3196.5–3906.9 Calculation
Nausea 44.3 39.9–48.7 Calculation
Fatigue/Asthenia 115.4 103.8–126.9 Calculation
Hypertension 12.9 11.6–14.2 Calculation
Proteinuria 115.4 5.8–7.1 Calculation
Utilities
Utility of PFS 0.65 0.26,0.87 [16]
Utility of OS 0.47 0.19,0.58 [16]
*The ranges of costs and utilities were obtained from local charge and literatures, respectively.
doi:10.1371/journal.pone.0032530.t003
Cost-Effectiveness of First-Line Therapy for mRCC
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32530published studies. The final adjusted Weibull PFS and OS
survival rates for the five strategies are shown in Figure 2.
Medical health resources and utilities
A Chinese healthcare system perspective was used to estimate
the costs in the current study. Direct medical costs, such as first
and second-line treatment-related medicines, radiological and
laboratory examinations, management of serious adverse events
(SAEs), physician visits, and BSC in the terminally ill, were
included. Indirect costs (e.g., lost productivity or premature death)
were not included [17]; the costs were converted into 2011 US
dollars (Table 3). All the unit costs of the health resources were
estimated using data from the local health system or the National
Development and Reform Commission (NDRC) of China [24].
The drug costs associated with each strategy were estimated
according to the following schedules. The interferon-alfa was
assumed to be administered by subcutaneous injection three times
per week in first cycle at 3 MU/dose in the first week, 6 MU/dose
in the second week, and 9 MU/dose thereafter. The subsequent
cycles involved three 9-MU/dose injections. The sunitinib was
assumed to be administered orally at 50 mg once daily for 4 weeks,
followed by 2 weeks off treatment. Bevacizumab 10 mg/kg or
placebo was assumed to be administered intravenously every 2
weeks. Interleukin-2 was assumed to be administered intravenous-
ly as 18 MU6body-surface area (m
2) daily for 5 days, once every 3
weeks. Sorafenib (a second-line treatment) was assumed to be
administered orally at 400 mg twice per day. To estimate the
dosage of the therapeutic agents, we assumed that a typical patient
weighed 65 kg and had a height of 1.64 m, resulting in a body-
surface area (BSA) of 1.72 m
2. We assumed that the unused drugs
in the open vials were discarded.
Based on a previous study [17], we assumed that 66% of
patients would receive second-line treatment when disease
progressed. Of those, nearly 33% received second-line targeted
therapy (14.2%, sunitinib; 12.2% sorafenib; 1.7% bevacizumab;
and 4.9% other targeted agents) [25]; 33.5% received either
interferon-alfa or interleukin-2 [17], regardless of the first-line
treatment. Because other targeted agents, such as everolimus and
axitinib, are unavailable in the Chinese market, we assumed that
the 4.9% receiving other targeted agents would switch to
sorafenib, based on expert opinion. Because no detailed BSC
treatment was reported in the clinical trial, we assumed that the
major cost would be pain medications (morphine sulphate) and
that the mean dosage would be 300 mg taken twice daily.
A previous study has shown that hematologic toxicities and
fatigue/asthenia are the main drivers of management costs in
sunitinib treatment and that proteinuria and fatigue/asthenia are
themain driversinbevacizumab plusinterferon-alfatreatment[26].
Our model incorporated these treatment-related AEs. Other high
incidence toxicities, such as nausea and hypertension, were also
Table 4. The base-case results for the five first-line therapies.
Treatment strategy
Model Outcome
* Interferon-alfa Bevacizumab plus interferon-alfa Sunitinib Interleukin-2
Interleukin-2 plus
interferon-alfa
Cost($) without SPAP
in progression-free stage 6802.82 157562.65 81728.07 4184.96 10464.30
in progressed stage 25817.48 21302.31 14250.28 23256.96 25159.11
total 32620.30 178864.96 95978.35 27441.92 35623.41
Cost($) with SPAP
in progression-free stage 6802.82 157562.65 15875.58 4184.96 10464.30
in progressed stage 19297.00 16075.92 11078.88 17484.91 18837.44
total 26099.82 173638.56 26954.46 21669.87 29301.74
Survival(Year)
in progression-free stage 0.59 1.04 1.71 0.67 0.58
in progressed stage 1.82 1.51 1.00 1.64 1.77
total 2.41 2.55 2.71 2.32 2.35
QALYs
in progression-free stage 0.35 0.61 0.98 0.40 0.34
in progressed stage 0.76 0.63 0.41 0.68 0.74
total 1.11 1.23 1.40 1.08 1.09
CER without SPAP 29285.33 145062.35 68765.81 25298.13 32798.34
CER with SPAP 23431.48 140823.65 19312.12 19977.00 26978.00
ICER without SPAP
# 177724.92 1021196.49 220384.01 5872545.72
Comment without SPAP Dominated Dominated
ICER with SPAP
# 152038.42 1024876.36 16992.99 5478038.63
Comment with SPAP Extended dominated Dominated Dominated
Abbreviations: SPAP, patient assistance program; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; LY, life-year; dominated, another strategy
was both more effective and less costly; extended dominated, another strategy achieved more effectiveness at a lower incremental cost-effectiveness ratio.
*All future costs and QALYs were discounted at 3%.
#Compared with Interleukin-2.
doi:10.1371/journal.pone.0032530.t004
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clinical practice and expert opinions. The incidences of SAEs were
sourced fromclinical trials (Table 2).The unit costs of treating SAEs
were estimated based on patient records in local hospitals.
The utility values of the PFS and PS states were derived from
previous published studies; 0.60 and 0.45 were assigned for PFS
and PS, respectively. Their standard errors were estimated at 10%
of the mean in our sensitivity analysis [16].
Sensitivity Analyses
One-way deterministic sensitivity analyses were used to identify
key model input parameters over the low/high values, which are
listed and illustrated in Table 2 and Table 3. The results are
presented as a tornado diagram based on the impact of the variable
on the incremental net health benefit, using 36the per capita GDP
of China as the threshold according to World Health Organiza-
tion(WHO) guidelines for cost-effectiveness analysis13,290
[27,28,29]. Probabilistic sensitivity analyses (PSA) were used to
evaluate the impact of uncertainty across all the parameters
simultaneously. The values of the input parameters were sampled
from lognormal distributions for costs and from b distributions for
utility values and probabilities or proportions with an assumed
standard deviation of 10% from mean values. Using these
distributions, 1,000 iterations of 1,000 simulated patients were run
for our analysis. The results are shown on a cost-effectiveness plane.
The outcomes projected from all 1,000 simulations were used to
plot acceptability curves, which estimated the willingness to pay
(WTP) threshold for an incremental unit of effectiveness.
Results
Base Case Result
The base case cost-effectiveness results (Table 4) were estimated with
a 10-year time horizon. Much longer periods of PFS achieved by the
targeted therapies (sunitinib and bevacizumab plus interferon-alfa)
resulted in longer survival times with more QALYs than could be
achieved with cytokine therapies (interferon-alfa, interleukin-2 and
interleukin-2 plus interferon-alfa). The sunitinib strategy produced an
average of 1.71 years in the PFS health state, compared to 0.59 years,
1.04 years, 0.67 years and 0.58 years for those receiving interferon-alfa,
bevacizumab plus interferon-alfa, interleukin-2 and interleukin-2 plus
interferon-alfa, respectively. The sunitinib strategy gained the greatest
number of QALYs over the course of the disease (1.40), compared to
1.11 QALYs for the interferon-alfa strategy and 1.23 for the
bevacizumab plus interferon-alfa strategy. The acquisition PFS time
of sunitinib largely explains its higher QALY output.
Table 4 also presents the total direct costs incurred by each
strategy. When no SPAP was offered, the targeted therapies were
more expensive. The total cost of bevacizumab plus interferon-alfa
was $178,864.96 ($157,562.65 for PFS), followed by $95,978.35 for
sunitinib ($81,728.07 for PFS), $35,623.41 for interleukin-2 plus
interferon-alfa ($10464.30), $32,620.30 for interferon-alfa ($6,802.82)
and $27,441.92 for interleukin-2 ($4,184.96). The results of the
scenario analysis indicated that the SPAP significantly reduced the
cost of the progression-free stage for the sunitinib strategy
($15,875.58). The relative cost-effectiveness analyses showed that
the bevacizumab plus interferon-alfa and interleukin-2 plus interfer-
on-alfa strategies were both dominated because their incremental
costs per QALY gained were $1,021,196.49 and $5,872,545.72,
respectively (Table 4 and Figure 3A). Regarding the SPAP, the
scenario analysis showed that the sunitinib strategy achieved
dominance; the bevacizumab plus interferon-alfa and interleukin-2
plus interferon-alfa strategies were dominated, and the interferon-alfa
strategy was extended dominated (Table 4 and Figure 3B).
Sensitivity Analyses
The tornado diagram (Figure 4) revealed that the net health
benefit of sunitinib vs. that of interleukin-2 was sensitive to some of
Figure 3. The cost-effectiveness of first-line strategies for mRCC patients. (A) without the SPAP; (B) with the SPAP. The x-axis indicates the
discounted lifetime quality-adjusted life-years (QALYs) for each strategy, and the y-axis indicates the total discounted lifetime costs (in US dollars). The
oblique line connects interleukin-2 and the most cost-effective strategies; strategies above the straight lines were dominated or extended dominated.
In the cost-effective plane, the values of the most incremental cost-effectiveness ratios (ICER) are depicted.
doi:10.1371/journal.pone.0032530.g003
Figure 4. A tornado diagram representing the net health benefit (in QALYs, with WTP=$13,290). The diagram determined by a one-way
sensitivity analysis of sunitinib vs. interleukin-2 for mRCC. The vertical line represents the base-case value for the net health benefit with
WTP=$13,290. PFS: progression-free survival; OS: overall survival; HR: hazard ratio. The results from the one-way sensitivity analysis indicated that the
most influential factor in the model was the 95% CI for the survival HR comparing sunitinib and interferon-alfa.
doi:10.1371/journal.pone.0032530.g004
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influential factor. Changing the PFS HR for sunitinib vs.
interferon-alfa in the range of the 95% CI had the effect of
changing the net health benefit significantly. At the upper
boundary of the HR, which resulted in a shorter PFS with
sunitinib, the net health benefit decreased to 26.26 QALYs
(WTP=$13,290). A longer PFS for sunitinib was observed at the
lower boundary of the HR, with the net health benefit increasing
to 23.81 QALYs. The other important drivers of the model were
the OS and PFS HR for interleukin-2, discount rate and utilities.
Other factors, such as the costs of managing SAEs, had little
impact.
The plot data from the PSA of 1,000 simulations revealed the
probabilities of meeting the ICER thresholds of $13,290 per
additional QALY for sunitinib over bevacizumab plus interferon-
alfa, interferon-alfa, interleukin-2 and interleukin-2 plus interferon-
alfa. The results are shown in Figure 5. With the SPAP, the
probabilities of achieving cost-effectiveness with sunitinib for
interferon-alfa, bevacizumab plus interferon-alfa, interleukin-2
and interleukin-2 plus interferon-alfa were 75.2%, 100%, 45.1%
and 95.3%, respectively, under the $13,290 threshold. Without the
sunitinib patient assistant program, the probabilities of achieving
cost-effectiveness with sunitinib were all zero when compared to all
other options, except for bevacizumab plus interferon-alfa (,99%).
Figure 5. The probabilistic results of the incremental cost-effectiveness differences. The comparisons were conducted between sunitinib
and (A) interferon-alfa, (B) bevacizumab plus interferon-alfa, (C) interleukin-2 and (D) interleukin-2 plus interferon-alfa for a cohort of 1,000 mRCC
patients with or without the SPAP. The y-axis represents the incremental costs. The x-axis represents the incremental quality-adjusted life years
(QALYs) gained. The ellipses surround 95% of the estimates. The dots found below the ICER threshold (the oblique lines) reflect simulations in which
the cost per additional QALY gained with sunitinib was below the ICER threshold.
doi:10.1371/journal.pone.0032530.g005
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preferred first-line strategies for mRCC when accounting for a
range of cost-per-QALY thresholds. The CEAC plot shows that
when no patient assistant program was offered, interleukin-2
achieved a nearly 89% likelihood, when the threshold level was
$13,290 (Figure 6A). When the program was offered, sunitinib
achieved likelihoods of nearly 40% (Figure 6B). Sunitinib and
interleukin-2 shared a likelihood of nearly 50% when the threshold
was $16,000. In China, local governments have the power to add
additional therapies ino basic medical services supplied by central
government according to their economic development level
[30,31]. Although interleukin-2 achieved the majority of cost-
effective probability at the threshold of 36average per capita GDP
of China, local governments are still expected to add new
therapies. Table 5 listed the cost-effective probabilities of 5
alternative strategies for 32 Chinese provinces at 36local per
capita GDP.
Discussion
New targeted therapies for the first-line treatment of mRCC
have increased survival rates a n di m p r o v e dq u a l i t yo fl i f e .
Nevertheless, the widespread use of new targeted therapies
comes with a dramatic increase in health care costs. A cost-
effectiveness evaluation of the recommended first-line therapies
in a health resource–limited setting is necessary to balance the
economic burden with the health benefits. Using indirect
comparison and decision-analytic modelling techniques, we
estimated the cost-effectiveness of five first-line mRCC strategies
over a lifetime horizon from the perspective of the Chinese
healthcare system.
Our results suggest that targeted therapies as first-line treatment
for mRCC provide more health benefits than do traditional
cytokine therapies. Although the enhanced survival benefits
resulting from the targeted therapies were not significant, the
prolonged PFS survival improved the benefit of the targeted
therapies over cytokines, which is an important reason why they
are now covered by some developed countries [18]. Nevertheless,
the gap between the costs of the targeted therapies and payment
capacity in a health resource-limited setting is still large. The
ICERs of sunitinib and bevacizumab plus interferon-alfa com-
pared to cytokine therapies are far greater than the societal
willingness-to-pay ($13,290for China). Interleukin-2 and interfer-
on-alfa are still practical options in a resource-limited setting. An
economic evaluation from the perspective of the UK NHS
estimated that the cost per QALY ranged from $109,522 for
sunitinib to $262,535 for bevacizumab plus interferon-alfa. The
two therapies could not be considered cost-effective at a
willingness-to-pay threshold of $46104/QALY, a result which is
consistent with our findings [32]. Although sunitinib showed cost-
effectiveness as a first-line mRCC treatment from the perspective
of the US, with a threshold of $50,000 to $100,000 per LY or
QALY, the results are not applicable to the developing regions of
the world because their thresholds are far less than $50,000.
If the sunitinib patient assistance program were available to
patients from poor regions, the sunitinib strategy might be the
optimal alternative option when the threshold of the willingness-
to-pay is greater than $16,000(Figure 6B). However, our analysis
showed the threshold of sunitinib strategy with the program is still
higher than the value of thrice the average Chinese GDP per
QALY, which indicates that adding sunitinib into the basic
medical service would not be cost-effective for Chinese central
government. The Chinese mainland has 32 provinces, among
which the per capita GDP differs significantly. In 2010, for
example, the per capita GDP ranged from $1,953 in Guizhou
province to $10,828 in the city of Shanghai as showing Table 5
[27]. Local government could consider covering sunitinib in their
local supplemental medical service according to local economic
development level. The results from Table 5 could supply the
decision information for local governments.
Figure 6. The cost-effectiveness acceptability curves for the five first-line strategies. (A) without the SPAP; (B) with the SPAP. The y-axis
indicates the probability that a strategy is cost-effective across the willingness to pay per QALY gained (x-axis). The bold vertical dashed line represent
the thresholds for China.
doi:10.1371/journal.pone.0032530.g006
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in China, so the physicians, decision makers or patients would
make the choice between sunitinib and bevacizumab. Our results
showed sunitinib provides more health benefits for lower costs
than bevacizumab plus interferon-alfa, regardless of the SPAP.
Our findings are consistent with a recently published study based
on the perspectives of the healthcare systems of the US and
Sweden, which used indirect comparisons of survival data. The
study showed that sunitinib as a first-line option for mRCC was a
cost-effective alternative to bevacizumab plus interferon-alfa,
because sunitinib was more effective and less costly [33].
The current study has some limitations. Using a Weibull
distribution to extrapolate the outcomes beyond the time horizon
of the trial follow-ups was an inevitablelimitation of this analysis.The
one-way sensitive analysis showed that the HR of the PFS and OS
had important impacts on the final result. The short median follow-
ups of the pivotal clinical trials did not provide enough survival data
for a comparison with the median survival that was estimated by the
model.At the same time, we did not consider the potential benefitsof
many of the uncertainties surrounding long-term survival rates, such
as new therapeutic agents for second-line therapy, which might
improve survival and life quality. Our results could be updated when
long-term data are available. However, no randomised controlled
trial has yet determined the long-term mRCC outcomes of first-line,
second-line, or third-line therapies to the point of death. Therefore, it
maybedifficulttoaccuratelymeasurethebenefitsoffirst-linetherapy
in future analyses, suggesting that a modelling technique may be the
only realistic alternative.
Another potential limitation was the choice the Chinese
healthcare system as our baseline perspective, which led to only
direct medical costs being included in the model. Considering a
societal perspective, which adds the additional burden of disease
on families and caregivers and other indirect costs, may increase
the costs associated with mRCC. As such, oral medications (e.g.,
Table 5. The cost-effective probabilities of five alternative strategies for 32 Chinese provinces with SPAP.
*
Region GDP($) interferon-alfa
Bevacizumab
plus interferon-alfa Sunitinib Interleukin-2
Interleukin-2
plus interferon-alfa
Mainland China 4430 1.4 0 44.7 53.9 0
Shanghai 10828 0.5 0 71.2 28.3 0
Tianjin 10400 0.5 0 69.4 30.1 0
Beijing 10378 0.5 0 69.4 30.1 0
Jiangsu 7682 0.4 0 61.6 38 0
Zhejiang 7390 0.4 0 60.6 39 0
Inner Mongolia 6969 0.4 0 58.9 40.7 0
Guangdong 6440 0.5 0 56.7 42.8 0
Liaoning 6172 0.6 0 55 44.4 0
Shandong 6078 0.6 0 54.5 44.9 0
Fujian 5748 0.5 0 52.4 47.1 0
Jilin 4614 1.1 0 45.7 53.2 0
Hebei 4152 1.8 0 42.9 55.3 0
Hubei 4079 1.9 0 42 56.1 0
Chongqing 4043 1.9 0 41.8 56.3 0
Shaanxi 3966 1.8 0 41.5 56.7 0
Heilongjiang 3946 1.8 0 41.3 56.9 0
Ningxia 3853 1.9 0 40.7 57.4 0
Shanxi 3759 1.9 0 40.2 57.9 0
Xinjiang 3670 2 0 39.4 58.6 0
Henan 3605 2.1 0 39.1 58.8 0
Hunan 3576 2.1 0 39 58.9 0
Qinghai 3545 2.1 0 38.7 59.2 0
Hainan 3496 2.3 0 38.2 59.5 0
Jiangxi 3127 2.5 0 36.7 60.8 0
Sichuan 3104 2.5 0 36.6 60.9 0
Guangxi 3050 2.5 0 36.2 61.3 0
Anhui 3045 2.5 0 36.1 61.4 0
Tibet 2497 3.1 0 32.2 64.7 0
Gansu 2379 3.2 0 31.6 65.2 0
Yunnan 2320 3.4 0 31.2 65.4 0
Guizhou 1953 4.1 0 29.4 66.5 0
*The probabilities were estimated at threshold of 36per capita GDP and presented as percentages, SPAP: sunitinib patient assistant program.
doi:10.1371/journal.pone.0032530.t005
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reduced toxicity may produce more favourable results. There is no
well-established method for incorporating such societal perspec-
tives when measuring the impact of cost-effectiveness of first-line
therapies for mRCC.
Because of the absence of head-to-head trials for the five first-
line strategies for mRCC, an indirect comparison was used in the
present analysis, which was another inevitable limitation. Similar
cohort characteristics for the five strategies were assumed in our
indirect comparison, and the results of the indirect comparison
were imputed into the analytical model. Nevertheless, when no
direct data is available, indirect comparisons using robust methods
are accepted by many authors worldwide. Future research should
directly compare the clinical efficacy of these strategies, especially
those of different targeted therapies.
Other important limitations of the current economic analysis
should be considered. In particular, we did not fully explore other
therapeutic strategies for mRCC treatment, such as temsirolimus,
everolimus and pazopanib, because they are still awaiting approval
from the State Food and Drug Administration of China [10].
Targeted therapies have shown more favourable health benefits
for certain subgroups [34]. Therefore, optimising the selection of
the patients receiving targeted therapies could increase the cost-
effectiveness of more expensive strategies. However, we did not
present economic outcomes for such subgroups, because we were
unable to adjust the five strategies in an indirect comparison
applicable to such subgroup cohorts. Finally, utility values were
obtained from literature published abroad and thus may not reflect
Chinese data. However, opinions from Chinese urologists and
oncologists suggest, quality of life of mRCC patients in China
should not be significantly different from external mRCC patients.
Although utilities have some impact on the result, the results of
sensitivity analysis indicated that the influence is limited.
Nevertheless, we are confident that the model faithfully repre-
sented the common clinical conditions of mRCC in a health
resource–limited setting. We believe this study has the potential to
be an important reference point for decision makers.
Conclusion
In the Chinese healthcare setting, a representative health
resource–limited region, traditional cytokine therapy is the cost-
effective option. When the threshold is higher than $16,000,
sunitinib might be a cost-effective therapy option compared to
bevacizumab plus interferon-alfa, interferon-alfa, interleukin-2
and interleukin-2 plus interferon-alfa, based on its superior PFS
benefit and Patient Assistance Program.
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